1 / 7

Clinical application

Clinical application. Dx exercise intolerance 1.1  VO 2 max   VO 2 AT 1.2 RER >1.2 (HRmax is not achieved) 1.3  breathing reserve < 20% (N=20-40%) 1.4  SaO 2 1.5 V E /VO 2 (ventilatory equivalent for oxygen) > 40 Dx exercise-induced bronchospasm (EIB)

borka
Download Presentation

Clinical application

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical application • Dx exercise intolerance 1.1  VO2max   VO2 AT 1.2 RER >1.2 (HRmax is not achieved) 1.3 breathing reserve < 20% (N=20-40%) 1.4  SaO2 1.5 VE/VO2(ventilatory equivalent for oxygen)> 40 • Dx exercise-induced bronchospasm (EIB) • Aerobic fitness evaluation

  2. Research study Optimal level of physical activity in children and adolescent with chronic lung disease

  3. To study the optimal level of physical activityin children and adolescents with CLD Objectives

  4. Experimental design Normal (n=18) CLD (n=18) Hx & PE VO2 at AT  correlate with physical activity PFT - Spirometry - Lung volumes - DLco Exercise stress test

  5. Results Chronic lung diseases: - Chronic interstitial lung 1 - Post lobectomy 5 - Pulmonary hemosiderosis 1 - Fibrotic lung 3 - BPD 2 - Asthma moderate persistent 6

  6. Abnormal PFT • Obstructive lung 7 (FEV1 80.0 + 12.9%pred) • Restrictive lung 7 (TLC 63.7 + 12.5%pred) • Diffusion defect 1 (DLco/VA = 77 %pred) • Hyperinflation 9 (RV/TLC 38.9 + 6.5%pred)

More Related